Ylva Maria Gjelsvik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ylva Maria Gjelsvik has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Tor Åge Myklebust
Department of Registration, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway
4 shared publications - Giske Ursin
The Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway; Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA
3 shared publications - Anders Meland
Norwegian School of Sport Sciences
2 shared publications - Cecilie Essholt Kiserud
Department of Oncology, Oslo University Hospital, Oslo, Norway
2 shared publications - Christine Marie Rygg Hoksnes
Department of Digital Health Research, Division of Medicine, Oslo University Hospital, Oslo, Norway
2 shared publications - Elin Børøsund
Department of Digital Health Research Division of Medicine Oslo University Hospital Oslo Norway
2 shared publications
Latest Publications
- Open Access
- 25 August 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1109-1116
Adverse health outcomes for prostate cancer patients treated with radiotherapy combined with androgen-deprivation therapy: A population-based, controlled study, from Norway
Background and purpose : The aim of this controlled cross-sectional, and population-based study was to evaluate adverse health outcomes (AHOs) 3 years after curative radiotherapy (RT) + androgen deprivation therapy (ADT). We also assessed Global Health/Quality of Life (QoL). Patients/material and methods: The Cancer Registry of Norway (CRN) provided data on prostate cancer (PCa) patients diagnosed in 2017–2019. All had been treated with RT+ ADT. All had completed EPIC-26 and EORTC QLQ-C30 about 3 years after RT start (n = 663). ADT duration was stratified: Short (< 9 months), intermediate (9–18 months) and long ADT (18–24 months). A group of controls were established from the general population (n = 1,817). Outcome measures were the urinary irritative/obstructive domain summary score (DSS), the bowel and sexual DSSs (EPIC-26) and QoL (EORTC QLQ-C30). Results: Compared to controls, patients had clinically important lower bowel, and sexual mean scores. Urinary irritative/obstructive DSS levels were similar. Overall, 43% (PCa patients) and 20% (controls) reported major sexual problems. In patients aged < 75 years, longer than short ADT duration significantly decreased sexual DSS. QoL was relatively unaffected. Low response rates, selection bias and a lack of pre-treatment data represent the studys´ limitations. Conclusion and Interpretation: Three years post-RT+ADT, PCa patients describe clinically important lower EPIC-26 bowel and sexual DSS compared to controls. Sexual domain levels decreased with increasing ADT duration, particularly in patients < 75 years. Our observations indicate worse AHOs than previously reported and should be considered during pre-treatment counselling of PCa patients.
- 25 August 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1109-1116
Open AccessAdverse health outcomes for prostate cancer patients treated with radiotherapy combined with androgen-deprivation therapy: A population-based, controlled study, from Norway
Background and purpose : The aim of this controlled cross-sectional, and population-based study was to evaluate adverse health outcomes (AHOs) 3 years after curative radiotherapy (RT) + androgen deprivation therapy (ADT). We also assessed Global Health/Quality of Life (QoL). Patients/material and methods: The Cancer Registry of Norway (CRN) provided data on prostate cancer (PCa) patients diagnosed in 2017–2019. All had been treated with RT+ ADT. All had completed EPIC-26 and EORTC QLQ-C30 about 3 years after RT start (n = 663). ADT duration was stratified: Short (< 9 months), intermediate (9–18 months) and long ADT (18–24 months). A group of controls were established from the general population (n = 1,817). Outcome measures were the urinary irritative/obstructive domain summary score (DSS), the bowel and sexual DSSs (EPIC-26) and QoL (EORTC QLQ-C30). Results: Compared to controls, patients had clinically important lower bowel, and sexual mean scores. Urinary irritative/obstructive DSS levels were similar. Overall, 43% (PCa patients) and 20% (controls) reported major sexual problems. In patients aged < 75 years, longer than short ADT duration significantly decreased sexual DSS. QoL was relatively unaffected. Low response rates, selection bias and a lack of pre-treatment data represent the studys´ limitations. Conclusion and Interpretation: Three years post-RT+ADT, PCa patients describe clinically important lower EPIC-26 bowel and sexual DSS compared to controls. Sexual domain levels decreased with increasing ADT duration, particularly in patients < 75 years. Our observations indicate worse AHOs than previously reported and should be considered during pre-treatment counselling of PCa patients.
- Open Access
- 2 July 2025
- Published by Springer Nature in Quality of Life Research
- Vol. 34 (9) , 2689-2700
A nationwide, longitudinal collection of patient-reported outcomes from prostate cancer patients and controls
Purpose: Patient-reported outcomes (PROs) provide valuable information on adverse effects of cancer treatment. The aim of this study was to describe the feasibility of a population-based PROs collection and identify factors affecting participation. Methods: A total of 13 595 patients diagnosed with prostate cancer (PCa) 2017–2019, along with 10 653 age- and region-matched men with no history of PCa (controls), were invited to a health survey collecting PROs shortly after diagnosis and again one and three years after the initial invitation. Invitations were sent by digital or regular mail. The survey included Norwegian translations of the EQ-5D-5L, EORTC QLQ-C30, and EPIC-26 instruments. We assessed participation rates in all three survey rounds. Results: We invited 90% of newly diagnosed PCa patients to round 1 of the survey. Participation was higher among patients (58%) than controls (34%), with the highest response rate among digitally invited patients aged 60–69 (66%). Among patients, 44% participated in both rounds 1 and 2. Almost one third (32%) of the invited patients participated in all three rounds. Factors associated with higher participation included digital invitation, higher education, lower age, and being treated with curative intent. Among participants treated with curative intent, 51% completed the first questionnaire before starting local treatment. Conclusions: National registry-based PROs data collection is feasible for both PCa patients and controls. However, both non-responder and attrition biases are likely to influence questionnaire results. Institutions conducting population-based health surveys should provide information on non-responders and attrition to aid interpretation of questionnaire data. Plain English summary: The Cancer Registry of Norway invited all Norwegian prostate cancer patients diagnosed between 2017 and 2019 to participate in a three-year health and quality of life survey. This study examines the success of the set-up of this nationwide survey. Patients received the first questionnaire at least six weeks after diagnosis, followed by the second and third questionnaires one and three years later. A control group consisting of men with no history of prostate cancer was also invited. We sent invitations as digital or regular (paper) mail. We used widely recognised questionnaires to assess health and quality of life in prostate cancer patients. Of the 13 595 patients invited, 58% participated in the first round. Among the 10 653 controls invited, 34% participated. The combined participation rate for patients in the first two rounds was 44%, and 32% for all three rounds. We found that digital invitation, higher education, lower age, and curative treatment were associated with higher response rates. We have shown that it is possible to conduct a registry-based national health survey over time among patients and controls. However, questionnaire results may not be representative due to non-responders and responders being different regarding, e.g., education, age and treatment. Therefore, those conducting population-based health surveys should provide information on non-responders and attrition to aid interpretation of questionnaire data.
- 2 July 2025
- Published by Springer Nature in Quality of Life Research
- Vol. 34 (9) , 2689-2700
Open AccessA nationwide, longitudinal collection of patient-reported outcomes from prostate cancer patients and controls
Purpose: Patient-reported outcomes (PROs) provide valuable information on adverse effects of cancer treatment. The aim of this study was to describe the feasibility of a population-based PROs collection and identify factors affecting participation. Methods: A total of 13 595 patients diagnosed with prostate cancer (PCa) 2017–2019, along with 10 653 age- and region-matched men with no history of PCa (controls), were invited to a health survey collecting PROs shortly after diagnosis and again one and three years after the initial invitation. Invitations were sent by digital or regular mail. The survey included Norwegian translations of the EQ-5D-5L, EORTC QLQ-C30, and EPIC-26 instruments. We assessed participation rates in all three survey rounds. Results: We invited 90% of newly diagnosed PCa patients to round 1 of the survey. Participation was higher among patients (58%) than controls (34%), with the highest response rate among digitally invited patients aged 60–69 (66%). Among patients, 44% participated in both rounds 1 and 2. Almost one third (32%) of the invited patients participated in all three rounds. Factors associated with higher participation included digital invitation, higher education, lower age, and being treated with curative intent. Among participants treated with curative intent, 51% completed the first questionnaire before starting local treatment. Conclusions: National registry-based PROs data collection is feasible for both PCa patients and controls. However, both non-responder and attrition biases are likely to influence questionnaire results. Institutions conducting population-based health surveys should provide information on non-responders and attrition to aid interpretation of questionnaire data. Plain English summary: The Cancer Registry of Norway invited all Norwegian prostate cancer patients diagnosed between 2017 and 2019 to participate in a three-year health and quality of life survey. This study examines the success of the set-up of this nationwide survey. Patients received the first questionnaire at least six weeks after diagnosis, followed by the second and third questionnaires one and three years later. A control group consisting of men with no history of prostate cancer was also invited. We sent invitations as digital or regular (paper) mail. We used widely recognised questionnaires to assess health and quality of life in prostate cancer patients. Of the 13 595 patients invited, 58% participated in the first round. Among the 10 653 controls invited, 34% participated. The combined participation rate for patients in the first two rounds was 44%, and 32% for all three rounds. We found that digital invitation, higher education, lower age, and curative treatment were associated with higher response rates. We have shown that it is possible to conduct a registry-based national health survey over time among patients and controls. However, questionnaire results may not be representative due to non-responders and responders being different regarding, e.g., education, age and treatment. Therefore, those conducting population-based health surveys should provide information on non-responders and attrition to aid interpretation of questionnaire data.
- Open Access
- 5 September 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (6) , 102219
Adverse Health Outcomes 3 Years after Radical Prostatectomy Compared with Men in the General Population: A Study from the Cancer Registry of Norway
- 5 September 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (6) , 102219
Open AccessAdverse Health Outcomes 3 Years after Radical Prostatectomy Compared with Men in the General Population: A Study from the Cancer Registry of Norway
- Open Access
- 24 May 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12, e47195
Coping After Breast Cancer: Protocol for a Randomized Controlled Trial of Stress Management eHealth Interventions
Background: One-third or more of breast cancer survivors report stress and other psychological and physical complaints that can negatively impact their quality of life. Psychosocial stress management interventions, shown to mitigate the negative impact of these complaints, can now be delivered as accessible and convenient (for the patient and provider) eHealth interventions. In this randomized controlled trial (RCT), Coping After Breast Cancer (CABC), 2 modified versions of the stress management eHealth intervention program StressProffen were created: one with predominantly cognitive behavioral stress management content (StressProffen-cognitive behavioral therapy intervention [StressProffen-CBI]) and another with predominantly mindfulness-based stress management content (StressProffen-mindfulness-based intervention [StressProffen-MBI]). Objective: This study aims to investigate the effects in breast cancer survivors of using StressProffen-CBI and StressProffen-MBI compared with a control group (treatment as usual). Methods: Women diagnosed with breast cancer (stage I-III, unequivocally human epidermal growth factor receptor 2–positive or estrogen receptor-negative tumors) or ductal carcinoma in situ (DCIS) aged 21-69 years who completed the Cancer Registry of Norway–initiated health survey on quality of life are invited to the CABC trial about 7 months after diagnosis. Women who give consent to participate are randomized (1:1:1) to either the StressProffen-CBI, StressProffen-MBI, or control group. Both StressProffen interventions consist of 10 modules of stress management content delivered through text, sound, video, and images. The primary outcome is between-group changes in perceived stress at 6 months, assessed with Cohen 10-item Perceived Stress Scale. The secondary outcomes comprise changes in quality of life, anxiety, depression, fatigue, sleep, neuropathy, coping, mindfulness, and work-related outcomes approximately 1, 2, and 3 years after diagnosis. Long-term effects of the interventions on work participation, comorbidities, relapse or new cancers, and mortality will be assessed using data from national health registries. Results: Recruitment is scheduled from January 2021 to May 2023. The goal is to recruit 430 participants (100 in each group). As of April 14 2023, 428 participants have been enrolled. Conclusions: The CABC trial is possibly the largest ongoing psychosocial eHealth RCT in patients with breast cancer. If 1 or both interventions prove to be effective in reducing stress and improving psychosocial and physical complains, the StressProffen eHealth interventions could be beneficial, inexpensive, and easily implementable tools for breast cancer survivors when coping with late effects after cancer and cancer treatments. Trial Registration: Clinicaltrials.gov NCT04480203; https://clinicaltrials.gov/ct2/show/NCT04480203 International Registered Report Identifier (IRRID): DERR1-10.2196/47195
- 24 May 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12, e47195
Open AccessCoping After Breast Cancer: Protocol for a Randomized Controlled Trial of Stress Management eHealth Interventions
Background: One-third or more of breast cancer survivors report stress and other psychological and physical complaints that can negatively impact their quality of life. Psychosocial stress management interventions, shown to mitigate the negative impact of these complaints, can now be delivered as accessible and convenient (for the patient and provider) eHealth interventions. In this randomized controlled trial (RCT), Coping After Breast Cancer (CABC), 2 modified versions of the stress management eHealth intervention program StressProffen were created: one with predominantly cognitive behavioral stress management content (StressProffen-cognitive behavioral therapy intervention [StressProffen-CBI]) and another with predominantly mindfulness-based stress management content (StressProffen-mindfulness-based intervention [StressProffen-MBI]). Objective: This study aims to investigate the effects in breast cancer survivors of using StressProffen-CBI and StressProffen-MBI compared with a control group (treatment as usual). Methods: Women diagnosed with breast cancer (stage I-III, unequivocally human epidermal growth factor receptor 2–positive or estrogen receptor-negative tumors) or ductal carcinoma in situ (DCIS) aged 21-69 years who completed the Cancer Registry of Norway–initiated health survey on quality of life are invited to the CABC trial about 7 months after diagnosis. Women who give consent to participate are randomized (1:1:1) to either the StressProffen-CBI, StressProffen-MBI, or control group. Both StressProffen interventions consist of 10 modules of stress management content delivered through text, sound, video, and images. The primary outcome is between-group changes in perceived stress at 6 months, assessed with Cohen 10-item Perceived Stress Scale. The secondary outcomes comprise changes in quality of life, anxiety, depression, fatigue, sleep, neuropathy, coping, mindfulness, and work-related outcomes approximately 1, 2, and 3 years after diagnosis. Long-term effects of the interventions on work participation, comorbidities, relapse or new cancers, and mortality will be assessed using data from national health registries. Results: Recruitment is scheduled from January 2021 to May 2023. The goal is to recruit 430 participants (100 in each group). As of April 14 2023, 428 participants have been enrolled. Conclusions: The CABC trial is possibly the largest ongoing psychosocial eHealth RCT in patients with breast cancer. If 1 or both interventions prove to be effective in reducing stress and improving psychosocial and physical complains, the StressProffen eHealth interventions could be beneficial, inexpensive, and easily implementable tools for breast cancer survivors when coping with late effects after cancer and cancer treatments. Trial Registration: Clinicaltrials.gov NCT04480203; https://clinicaltrials.gov/ct2/show/NCT04480203 International Registered Report Identifier (IRRID): DERR1-10.2196/47195
- Open Access
- 12 March 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Coping After Breast Cancer: Protocol for a Randomized Controlled Trial of Stress Management eHealth Interventions (Preprint)
BACKGROUND One-third or more of breast cancer survivors report stress and other psychological and physical complaints that can negatively impact their quality of life. Psychosocial stress management interventions, shown to mitigate the negative impact of these complaints, can now be delivered as accessible and convenient (for the patient and provider) eHealth interventions. In this randomized controlled trial (RCT), Coping After Breast Cancer (CABC), 2 modified versions of the stress management eHealth intervention program StressProffen were created: one with predominantly cognitive behavioral stress management content (StressProffen-cognitive behavioral therapy intervention [StressProffen-CBI]) and another with predominantly mindfulness-based stress management content (StressProffen-mindfulness-based intervention [StressProffen-MBI]). OBJECTIVE This study aims to investigate the effects in breast cancer survivors of using StressProffen-CBI and StressProffen-MBI compared with a control group (treatment as usual). METHODS Women diagnosed with breast cancer (stage I-III, unequivocally human epidermal growth factor receptor 2–positive or estrogen receptor-negative tumors) or ductal carcinoma in situ (DCIS) aged 21-69 years who completed the Cancer Registry of Norway–initiated health survey on quality of life are invited to the CABC trial about 7 months after diagnosis. Women who give consent to participate are randomized (1:1:1) to either the StressProffen-CBI, StressProffen-MBI, or control group. Both StressProffen interventions consist of 10 modules of stress management content delivered through text, sound, video, and images. The primary outcome is between-group changes in perceived stress at 6 months, assessed with Cohen 10-item Perceived Stress Scale. The secondary outcomes comprise changes in quality of life, anxiety, depression, fatigue, sleep, neuropathy, coping, mindfulness, and work-related outcomes approximately 1, 2, and 3 years after diagnosis. Long-term effects of the interventions on work participation, comorbidities, relapse or new cancers, and mortality will be assessed using data from national health registries. RESULTS Recruitment is scheduled from January 2021 to May 2023. The goal is to recruit 430 participants (100 in each group). As of April 14 2023, 428 participants have been enrolled. CONCLUSIONS The CABC trial is possibly the largest ongoing psychosocial eHealth RCT in patients with breast cancer. If 1 or both interventions prove to be effective in reducing stress and improving psychosocial and physical complains, the StressProffen eHealth interventions could be beneficial, inexpensive, and easily implementable tools for breast cancer survivors when coping with late effects after cancer and cancer treatments. CLINICALTRIAL Clinicaltrials.gov NCT04480203; https://clinicaltrials.gov/ct2/show/NCT04480203 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/47195
- 12 March 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessCoping After Breast Cancer: Protocol for a Randomized Controlled Trial of Stress Management eHealth Interventions (Preprint)
BACKGROUND One-third or more of breast cancer survivors report stress and other psychological and physical complaints that can negatively impact their quality of life. Psychosocial stress management interventions, shown to mitigate the negative impact of these complaints, can now be delivered as accessible and convenient (for the patient and provider) eHealth interventions. In this randomized controlled trial (RCT), Coping After Breast Cancer (CABC), 2 modified versions of the stress management eHealth intervention program StressProffen were created: one with predominantly cognitive behavioral stress management content (StressProffen-cognitive behavioral therapy intervention [StressProffen-CBI]) and another with predominantly mindfulness-based stress management content (StressProffen-mindfulness-based intervention [StressProffen-MBI]). OBJECTIVE This study aims to investigate the effects in breast cancer survivors of using StressProffen-CBI and StressProffen-MBI compared with a control group (treatment as usual). METHODS Women diagnosed with breast cancer (stage I-III, unequivocally human epidermal growth factor receptor 2–positive or estrogen receptor-negative tumors) or ductal carcinoma in situ (DCIS) aged 21-69 years who completed the Cancer Registry of Norway–initiated health survey on quality of life are invited to the CABC trial about 7 months after diagnosis. Women who give consent to participate are randomized (1:1:1) to either the StressProffen-CBI, StressProffen-MBI, or control group. Both StressProffen interventions consist of 10 modules of stress management content delivered through text, sound, video, and images. The primary outcome is between-group changes in perceived stress at 6 months, assessed with Cohen 10-item Perceived Stress Scale. The secondary outcomes comprise changes in quality of life, anxiety, depression, fatigue, sleep, neuropathy, coping, mindfulness, and work-related outcomes approximately 1, 2, and 3 years after diagnosis. Long-term effects of the interventions on work participation, comorbidities, relapse or new cancers, and mortality will be assessed using data from national health registries. RESULTS Recruitment is scheduled from January 2021 to May 2023. The goal is to recruit 430 participants (100 in each group). As of April 14 2023, 428 participants have been enrolled. CONCLUSIONS The CABC trial is possibly the largest ongoing psychosocial eHealth RCT in patients with breast cancer. If 1 or both interventions prove to be effective in reducing stress and improving psychosocial and physical complains, the StressProffen eHealth interventions could be beneficial, inexpensive, and easily implementable tools for breast cancer survivors when coping with late effects after cancer and cancer treatments. CLINICALTRIAL Clinicaltrials.gov NCT04480203; https://clinicaltrials.gov/ct2/show/NCT04480203 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/47195